Unveiling the Role of the Cellular Tumor Microenvironment and the Therapeutic Targets it Provides in Cutaneous T-Cell Lymphoma

被引:0
|
作者
Chinas, Nikolaos A. [1 ]
Kaliampou, Stella [1 ]
Nikolaou, Vasiliki [1 ]
机构
[1] Natl & Kapodistrian Univ Athens, Andreas Sygros Hosp Skin & Venereal Dis, Med Sch, Dept Dermatol Venereol 1, Athens, Greece
关键词
CTCL; Mycosis Fungoides; S & eacute; zary Syndrome; Tumor Microenvironment; Cells; Therapeutic Targets; PROTEASOME INHIBITOR BORTEZOMIB; MYCOSIS-FUNGOIDES; SEZARY-SYNDROME; DISEASE PROGRESSION; LESIONAL SKIN; SERUM-LEVELS; MUCIN; EXPRESSION; ACTIVATION; SUBSETS;
D O I
10.1007/s11912-025-01646-6
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose of ReviewCutaneous T-Cell Lymphoma (CTCL) poses challenges both in diagnosis and prognosis. The purpose of this review is to address the role of profiling immune and non-immune cells in the tumor microenvironment (TME) as it provides information for better diagnosis, prognosis, biomarker discovery, and personalized treatment strategies.Recent FindingsRecent evidence suggests that the progression of CTCL is closely linked to the Tumor Microenvironment (TME) which comprises various cell types including immune cells, stromal cells, blood vessels, and the extracellular matrix. Cell profiling within the TME demonstrates the perplexity of intracellular communication of the different cell fates and their mediators as the disease progresses.SummaryCTCL as a rare form of non-Hodgkin lymphoma often misdiagnosed due to its similarity to other skin conditions. It encompasses diseases like Mycosis fungoides (MF) and S & eacute;zary Syndrome (SS), with the latter being more severe. Advances in studying the TME have shown its pivotal role in CTCL progression, highlighting the need for comprehensive cell profiling to enhance diagnosis, prognosis, and treatment personalization.
引用
收藏
页码:415 / 430
页数:16
相关论文
共 50 条
  • [41] In vivo modelling of cutaneous T-cell lymphoma: The role of SOCS1
    Luo, Yixin
    Vermeer, Maarten H.
    de Gruijl, Frank R.
    Zoutman, Willem H.
    Sluijter, Marjolein
    van Hall, Thorbald
    Tensen, Cornelis P.
    FRONTIERS IN ONCOLOGY, 2022, 12
  • [42] Phototherapy for Cutaneous T-Cell Lymphoma
    Marka, Arthur
    Carter, Joi B.
    DERMATOLOGIC CLINICS, 2020, 38 (01) : 127 - +
  • [43] Management of cutaneous T-cell lymphoma
    Duhovic, Chris
    Child, Fiona
    Wain, E. Mary
    CLINICAL MEDICINE, 2012, 12 (02) : 160 - 164
  • [44] The immunopathogenesis and immunotherapy of cutaneous T cell lymphoma: Pathways and targets for immune restoration and tumor eradication
    Durgin, Joseph S.
    Weiner, David M.
    Wysocka, Maria
    Rook, Alain H.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 84 (03) : 587 - 595
  • [45] Prognostic Significance of Serum Copper in Patients With Cutaneous T-cell Lymphoma
    Vonderheid, Eric C.
    Martinez, Andrew R.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2019, 19 (04) : 228 - +
  • [46] Novel Biomarkers, Dysregulated Epigenetics, and Therapy in Cutaneous T-cell Lymphoma
    Wong, Henry K.
    DISCOVERY MEDICINE, 2013, 16 (87) : 71 - 78
  • [47] Genetic and epigenetic insights into cutaneous T-cell lymphoma
    Tensen, Cornelis P.
    Quint, Koen D.
    Vermeer, Maarten H.
    BLOOD, 2022, 139 (01) : 15 - 33
  • [48] Canine cutaneous epitheliotropic T-cell lymphoma: a review
    Fontaine, J.
    Bovens, C.
    Bettenay, S.
    Mueller, R. S.
    VETERINARY AND COMPARATIVE ONCOLOGY, 2009, 7 (01) : 1 - 14
  • [49] Denileukin diftitox for the treatment of cutaneous T-cell lymphoma
    Prince, H. Miles
    Newland, Kate M.
    EXPERT OPINION ON ORPHAN DRUGS, 2014, 2 (06): : 625 - 634
  • [50] MicroRNAs in Cutaneous T-Cell Lymphoma: The Future of Therapy
    Kohnken, Rebecca
    Mishra, Anjali
    JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2019, 139 (03) : 528 - 534